PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|October 7, 2022
Thermo Fisher Scientific Launches Large-Scale Cell Culture Harvesting Solution
Author(s)Pharmaceutical Technology Editors
Thermo Fisher’s new centrifuge technology is designed to enable efficient, sustainable cell culture harvesting.
Advertisement
Thermo Fisher Scientific recently announced the DynaSpin Single-Use Centrifuge system, a centrifuge that is specifically designed to provide optimal single-use solution for large-scale cell culture harvesting. The system aims to improve and streamline the process by reducing the number of depth filtration cartridges required to complete the harvest process.
According to a Sept. 28, 2022 press release, by reducing the number of filters required for harvesting, the DynaSpin offers upwards of six-fold reduction in material requirements. This is estimated to eliminate approximately 70% of waste compared to traditional harvest systems.
“We developed the DynaSpin system with an eye on efficiently harvesting biologics at large-scale,” said Srini Paluri, vice-president and general manager, Bioprocess Equipment & Automation, Thermo Fisher Scientific, in the release. “It was critical that the solution also consider the environment while outperforming traditional harvest solutions and delivering consistent product yields to our customers.”
The DynaSpin is designed for scalability, rapid changeover, reduced downtime, and lower risk of contamination to the workflow, according to the release. It also features configurable user access, audit trail, and batch reporting.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement